The Patent Finder

Terms ending in 2028

Pharmacyclics, Inc.

Every in-force patent on Pharmacyclics, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 7,825,118Inhibitors of Bruton's Tyrosine Kinase
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 7,838,234Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 9,128,096Methods for Determining Cancer Resistance to Histone Deacetylase Inhibitors
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 8,748,468MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIa MODULATOR
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
US 8,338,416Indole Derivatives as Inhibitors of Histone Deacetylase
In force
 · High confidence
Pharmacyclics LLCIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited